- Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial
Circulation · 2023
- 5‐Year simulation of diabetes‐related complications in people treated with tirzepatide or semaglutide versus insulin glargine
Diabetes Obesity and Metabolism · 2023
- Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction
Journal of the American College of Cardiology · 2023
- Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Nature Medicine · 2023
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
New England Journal of Medicine · 2023
- Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Cardiovascular Diabetology · 2023
- The Effect of Additional Treatment with Empagliflozin or Semaglutide on Endothelial Function and Arterial Stiffness in Subjects with Type 1 Diabetes Mellitus—ENDIS Study
Pharmaceutics · 2023
- Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype
JACC Heart Failure · 2023
- The cardioprotective effect of human glucagon‐like peptide‐1 receptor agonist (semaglutide) on cisplatin‐induced cardiotoxicity in rats: Targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways
Cell Biochemistry and Function · 2023
- Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of <scp>SOUL</scp> , a randomized trial
Diabetes Obesity and Metabolism · 2023
- The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Nephrology Dialysis Transplantation · 2023
- Semaglutide Pretreatment Induces Cardiac Autophagy to Reduce Myocardial Injury in Septic Mice
Discovery Medicine · 2023
- Risk of pulmonary aspiration during semaglutide use and anesthesia in a fasting patient: a case report with tomographic evidence
Einstein (São Paulo) · 2023
- Underrepresentation of Women in Recent Landmark Kidney Trials: The Gender Gap Prevails
Kidney International Reports · 2022
- Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
Frontiers in Endocrinology · 2022
- Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk
Diabetes Care · 2022
- Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective
Saudi Pharmaceutical Journal · 2022
- Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus
Diabetes Therapy · 2021
- Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects
Clinical Pharmacokinetics · 2021
- Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
Journal of Clinical Pharmacy and Therapeutics · 2020
- The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials
Diabetes Obesity and Metabolism · 2020
- Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity
Journal of the Endocrine Society · 2020
- Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis
Current Diabetes Reviews · 2018
- Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Clinical Pharmacokinetics · 2018
- Liraglutide causes large and rapid epicardial fat reduction
Obesity · 2017